Québec International, corporation de développement économique pour la région de QuébecQuébec International, corporation de développement économique pour la région de Québec

News

Opsens gets clearance to sell FFR products in the United States

News - Opsens Inc. today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the OptoWire and OptoMonitor, its products developed to measure Fractional Flow Reserve (“FFR”). This measure is used to optimize the diagnostic and guide the treatment of patients with coronary heart disease. This clearance gives Opsens permission to sell its FFR products in the United States, the world’s largest FFR market.

LeddarTech introduces LeddarCore sensor ICs for high-volume applications

News - LeddarTech® today announced the upcoming launch of LeddarCore™, a new line of sensor ICs designed to offer unmatched integration capabilities for the development and production of high-volume applications.

Cloud services: Microsoft chooses Québec City for one of its data centres

News - Québec International welcomes the announcement by American giant Microsoft to provide commercial cloud services from Québec City and Toronto.

New portal for Canadian clinical research capabilities launched: CCTAM

News - The Canadian Clinical Trials Asset Map (CCTAM), a pan-Canadian database showcasing Canada’s clinical research capacities was launched this morning in front of an audience of scientists, researchers and policymakers, by Senator Kelvin K. Ogilvie.

Sweet dreams: Quebec chocolate entrepreneur aiming for global expansion

News - Is Dominique Brown the world’s coolest dad? His kids must certainly think so. A decade after he sold Beenox, a video-game development company he founded in 2000 at age 21, to multinational giant Activision for megabucks, the Quebec City entrepreneur is now investing his time and money in a unique chocolate-making company.

Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.

News - Aeterna Zentaris Inc. and EMD Serono, Inc., the U.S. and Canadian biopharmaceutical businesses of Merck KGaA, Darmstadt, Germany, today announced the finalization of a promotional services agreement that will allow Aeterna Zentaris to promote Saizen® [somatropin (rDNA origin) for injection] to designated medical professionals in specified territories in the United States. Saizen® is a recombinant human Growth Hormone (r-hGH) registered in the U.S. for the treatment of growth hormone deficiency (GHD) in children and adults.

Opsens announces first use of its FFR products by Dr. Nico Pijls

News - Opsens inc. is pleased to announce the first use of the OptoWire and OptoMonitor, its products to measure Fractional Flow Reserve ("FFR"), by Dr. Nico Pijls in Eindhoven, the Netherlands. Opsens' FFR products are designed to optimize the diagnosis and guide the treatment of patients with coronary heart disease.

DiagnoCure's new prostate cancer multimarker urine test featured at a recent press event of the American Urological Association

News - DiagnoCure Inc.reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA) held from May 15 to May 19 in New Orleans, Louisiana.

CO2 Solutions Announces Successful Start-Up of Demonstration Plant

News - CO2 Solutions Inc., the leader in the field of enzyme-enabled carbon capture technology, today announced that its 10 tonnes per day (tpd) CO2 capture demonstration project at Salaberry-de-Valleyfield, Quebec, has commenced in line with the Company`s timeline as communicated previously.

Medicago to build $245 M production facility in Quebec City

News - Medicago, a major Canadian biotech company and an international leader in the development and production of plant-based vaccines and therapeutics, is proud to announce that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago’s Quebec City office and laboratories. The project is expected to generate more than $461 million in direct and indirect economic benefits over the next five years.

Newsletter

Subscribe to our newsletter for interesting news and information.

Print this page